News

Researchers found no anti–HPA-1a antibodies that bind only to αvβ3 in maternal blood from patients with FNAIT.

A targeted immunotherapy using a specially designed fusion protein for the treatment of FNAIT has shown early promise in animal models.

Biologics like nipocalimab will soon offer a targeted approach that could transform FNAIT prevention and management.

A six-month transfusion medicine program enhanced the trainees’ clinical skills, helping to prevent complications associated with conditions like FNAIT.

Preventative intravenous immunoglobulin therapy can lower risks in FNAIT, though some experts disagree on when and how to use it.

Authors of the review stated routine screening during pregnancy for FNAIT would allow for timely treatment and help prevent brain bleeds.

Researchers developed a three-dimensional model to study the mechanisms behind intraventricular hemorrhage.

A woman who experienced a miscarriage did not respond to several platelet transfusions due to the presence of anti-platelet antibodies.

Thrombocytopenia, a platelet disorder linked to FNAIT, was a major predictor of serious illness in preterm infants in a recent study.

Advancements in the preparation of platelet concentrates, often required to treat FNAIT, have the potential to improve patient care.